<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00709553</url>
  </required_header>
  <id_info>
    <org_study_id>D4320C00010</org_study_id>
    <secondary_id>ZD4054EudraCt 2008-002764-35</secondary_id>
    <nct_id>NCT00709553</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study to Asses Multiple Doses of ZD4054 (Zibotentan)</brief_title>
  <official_title>A Randomised, Open-label, Crossover, Phase I Study to Assess the Effect of Multiple Oral Doses of ZD4054 (Zibotentan) on the Pharmacokinetics of a CYP450 3A Probe (Midazolam) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to to assess the effect of multiple oral doses of ZD4054
      (Zibotentan) on the pharmacokinetics of a CYP450 3A Probe (midazolam) in healthy male
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK variables</measure>
    <time_frame>Frequent sampling occasions during study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables (adverse events, ECG, blood pressure, pulse, safety lab)</measure>
    <time_frame>During the whole treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>midazolam, one single dose of 705mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZD4054(Zibotentan)- 10mg od, 7 days + midazolam (one single dose of 7.5 mg on day 6 )</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>DormicumÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD4054</intervention_name>
    <description>ZD4054 10 mg od</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Zibotentan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 18 and 30 kg/m2

          -  Medical and surgical history and physical examination without any clinically
             significant findings

          -  Normal resting ECG with QTcB interval &lt;450ms

        Exclusion Criteria:

          -  Definite or suspected personal history or family history of hypersensitivity to drugs
             that are endothelin antagonists; ie, ambrisentan, artrasentan, sitaxsetan and bosentan

          -  Healthy volunteer has a known hypersensitivity to midazolam or any of the excipients
             of the midazolam tablet

          -  Medical diagnosis of migraine with an attack during the 12 months prior to Screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Morris</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca, Medical Science Director</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dago Mazur</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2008</study_first_submitted>
  <study_first_submitted_qc>July 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2008</study_first_posted>
  <last_update_submitted>September 27, 2010</last_update_submitted>
  <last_update_submitted_qc>September 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Thomas Morris, BSc MB BCh MRCP FFPM, Medical Science Director, ZD4054</name_title>
    <organization>AstraZeneca R&amp;D Alderley Park</organization>
  </responsible_party>
  <keyword>ZD4054</keyword>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

